SteadyMed Submits Ty
SteadyMed Submits Type A Meeting Request Package to FDA
September 28, 2017 08:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Sept. 28, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Receives R
SteadyMed Receives Refusal to File Letter from FDA for Trevyent® New Drug Application
August 31, 2017 06:45 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Reports Se
SteadyMed Reports Second Quarter 2017 Financial Results and Provides Corporate Update
August 11, 2017 08:30 ET | SteadyMed Therapeutics
Submitted New Drug Application for Trevyent for the Treatment of Pulmonary Arterial Hypertension On track for Mid-2018 U.S. Commercial Launch, Subject to FDA Approval SAN RAMON, Calif., Aug. 11,...
SteadyMed to Present
SteadyMed to Present at the 2017 Wedbush PacGrow Healthcare Conference
August 09, 2017 08:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Appoints J
SteadyMed Appoints Jeff Myers M.D. Ph.D. Vice President of Medical Affairs
July 31, 2017 08:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., July 31, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Submits Ne
SteadyMed Submits New Drug Application for Trevyent®
June 30, 2017 14:35 ET | SteadyMed Therapeutics
SAN RAMON, Calif., June 30, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed to Present
SteadyMed to Present at the 2017 JMP Securities Life Sciences Conference
June 13, 2017 08:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., June 13, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Raises Add
SteadyMed Raises Additional Capital from Key Institutional Shareholder
May 26, 2017 08:42 ET | SteadyMed Therapeutics
SAN RAMON, Calif., May 26, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...
SteadyMed Reports Fi
SteadyMed Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 12, 2017 08:30 ET | SteadyMed Therapeutics
Raised $28.2 Million in Net Proceeds in a Private PlacementReceived a Favorable IPR Ruling Invalidating United Therapeutics’ ‘393 PatentCompleted a Clinical Validation Study for Trevyent®On Track to...
SteadyMed Receives U
SteadyMed Receives USPTO Notice of Allowance for Patent Related to Key PatchPump® Technology
May 02, 2017 08:30 ET | SteadyMed Therapeutics
SAN RAMON, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and...